ISCT Webinar - Bioreactors for Cell Therapies: Current Advancements in Autologous, Allogeneic and Tissue Engineering
Sponsored by GE Healthcare
Organized by the ISCT Process and Product Development Subcommittee
Date: Wednesday, December 14, 2016
Time: 09:00 PST, 12:00 EST, 17:00 GMT, 18:00 CET
Chair: Shannon Eaker, PhD, GE Cell Therapy, USA
- Julie G. Allickson, PhD, Director, Regenerative Medicine Clinical Center, Wake Forest Institute for Regenerative Medicine
- Pascal Beauchesne, PhD, Senior Scientist, Process and Analytical Development, Juno Therapeutics
- Biren Mistry, MS, Senior Bioengineer, Bioprocess Development, Celgene Cellular Therapeutics
About the Webinar:
The webinar will focus on the use of bioreactors within cellular therapy processes, with an emphasis on tissue engineering, allogeneic, and autologous applications. For tissue engineering, customizing bioreactor variables play an important role in the process for development of a tissue engineered organ.
For allogeneic or autologous cell therapies, bioreactor development emphasizes meeting product demand, maintaining product quality, and improving process logistics. Each of these cell therapy modalities has its unique challenges for bioreactor development. Product success can only be enabled by overcoming these challenges.
- Understand current bioreactor use within tissue engineering, allogeneic, and autologous cell therapy processes.
- Monitor and controlling process parameters within bioreactors.
- Scale-up and scale-out requirements.
- Process transfer from flask-based to bioreactors.
- Future technology needs.